About: Tegaserod

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org:8891

Tegaserod is a 5-HT4 agonist manufactured by Novartis and sold under the names Zelnorm and Zelmac for the management of irritable bowel syndrome and constipation. Approved by the FDA in 2002, it was subsequently removed from the market in 2007 due to FDA concerns about possible adverse cardiovascular effects. Before then, it was the only drug approved by the United States Food and Drug Administration to help relieve the abdominal discomfort, bloating, and constipation associated with irritable bowel syndrome. Its use was also approved to treat chronic idiopathic constipation.

Property Value
dbo:abstract
  • Tegaserod ist ein Arzneistoff zur Behandlung des Reizdarmsyndroms (IBS) mit Verstopfung (Obstipation) bei Frauen. Unter den Handelsnamen Zelnorm (Novartis) wurde es 2002 in den USA zugelassen. Die Wirkung entsteht durch Aktivierung der 5-HT-Rezeptoren (Serotoninagonist). (de)
  • تيجاسيرود أو تيغاسيرود (بالإنجليزية: Tegaserod)‏ هو ناهض 5-HT4 مصنع من قبل شركة Novartis ويباع تحت اسم Zelnorm وZelmac ويستخدم لعلاج متلازمة القولون العصبي والإمساك. (ar)
  • El Tegaserod es un fármaco agonista parcial de los receptores de serotonina 5-HT4, desarrollado por Novartis. (es)
  • Tegaserod is a 5-HT4 agonist manufactured by Novartis and sold under the names Zelnorm and Zelmac for the management of irritable bowel syndrome and constipation. Approved by the FDA in 2002, it was subsequently removed from the market in 2007 due to FDA concerns about possible adverse cardiovascular effects. Before then, it was the only drug approved by the United States Food and Drug Administration to help relieve the abdominal discomfort, bloating, and constipation associated with irritable bowel syndrome. Its use was also approved to treat chronic idiopathic constipation. (en)
  • Tegaserod è un agonista dei recettori 5-HT4, utilizzato per il trattamento della sindrome dell'intestino irritabile e della costipazione. Il farmaco è prodotto e venduto dalla società farmaceutica Novartis con il nome commerciale di Zelnorm e Zelmac. Approvato dalla Food and Drug Administration (FDA) degli USA nel 2002, è stato successivamente ritirato dal mercato nel 2007, a causa delle preoccuppazioni della FDA circa i possibili effetti avversi cardiovascolari. Prima di allora tegaserod era l'unico farmaco approvato dalla FDA per contribuire ad alleviare il disagio addominale, il senso di gonfiore e la costipazione associata alla sindrome del colon irritabile. Il suo uso era stato approvato anche per il trattamento della costipazione idiopatica cronica. Attualmente, tegaserod può essere utilizzato solo in situazioni di emergenza e solo previa autorizzazione da parte della FDA. (it)
  • Tegaserode é um fármaco agonista parcial dos receptores 5-HT4 da serotonina. Tem como principais funções agir contra os efeitos da constipação intestinal crônica e síndrome do cólon irritável. (pt)
  • Тегасерод — синтетичний лікарський засіб, що застосовується для лікування захворювань травної системи, який є стимулятором серотонінових рецепторів, та має прокінетичну дію, що застосовується перорально. (uk)
dbo:alternativeName
  • Zelnorm, Zelmac (en)
dbo:bioavailability
  • 10.000000 (xsd:float)
dbo:casNumber
  • 145158-71-0
dbo:chEMBL
  • 76370
dbo:drugbank
  • DB01079
dbo:fdaUniiCode
  • 458VC51857
dbo:kegg
  • D02730
dbo:pubchem
  • 5362436
dbo:thumbnail
dbo:wikiPageID
  • 1167677 (xsd:integer)
dbo:wikiPageLength
  • 7194 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1083517293 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • A06 (en)
dbp:atcSuffix
  • AX06 (en)
dbp:bioavailability
  • 10.0
dbp:c
  • 16 (xsd:integer)
dbp:casNumber
  • 145158 (xsd:integer)
dbp:chembl
  • 76370 (xsd:integer)
dbp:chemspiderid
  • 10609889 (xsd:integer)
dbp:drugbank
  • DB01079 (en)
dbp:eliminationHalfLife
  • 18000.0
dbp:excretion
  • Fecal and renal (en)
dbp:h
  • 23 (xsd:integer)
dbp:image
  • Tegaserod ball-and-stick model.png (en)
dbp:iupacName
  • -2 (xsd:integer)
dbp:iupharLigand
  • 226 (xsd:integer)
dbp:kegg
  • D02730 (en)
dbp:legalUsComment
  • Usage requires authorization from the FDA (en)
dbp:metabolism
  • Gastric and hepatic (en)
dbp:n
  • 5 (xsd:integer)
dbp:o
  • 1 (xsd:integer)
dbp:pregnancyAu
  • B3 (en)
dbp:pregnancyUs
  • B (en)
dbp:proteinBound
  • 98.0
dbp:pubchem
  • 5362436 (xsd:integer)
dbp:routesOfAdministration
  • Oral (en)
dbp:smiles
  • CCCCCNCNN=Cc1c[nH]c2ccccc12 (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • IKBKZGMPCYNSLU-RGVLZGJSSA-N (en)
dbp:tradename
  • Zelnorm, Zelmac (en)
dbp:unii
  • 458 (xsd:integer)
dbp:verifiedfields
  • changed (en)
dbp:verifiedrevid
  • 470478621 (xsd:integer)
dbp:watchedfields
  • changed (en)
dbp:width
  • 250 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • Tegaserod ist ein Arzneistoff zur Behandlung des Reizdarmsyndroms (IBS) mit Verstopfung (Obstipation) bei Frauen. Unter den Handelsnamen Zelnorm (Novartis) wurde es 2002 in den USA zugelassen. Die Wirkung entsteht durch Aktivierung der 5-HT-Rezeptoren (Serotoninagonist). (de)
  • تيجاسيرود أو تيغاسيرود (بالإنجليزية: Tegaserod)‏ هو ناهض 5-HT4 مصنع من قبل شركة Novartis ويباع تحت اسم Zelnorm وZelmac ويستخدم لعلاج متلازمة القولون العصبي والإمساك. (ar)
  • El Tegaserod es un fármaco agonista parcial de los receptores de serotonina 5-HT4, desarrollado por Novartis. (es)
  • Tegaserod is a 5-HT4 agonist manufactured by Novartis and sold under the names Zelnorm and Zelmac for the management of irritable bowel syndrome and constipation. Approved by the FDA in 2002, it was subsequently removed from the market in 2007 due to FDA concerns about possible adverse cardiovascular effects. Before then, it was the only drug approved by the United States Food and Drug Administration to help relieve the abdominal discomfort, bloating, and constipation associated with irritable bowel syndrome. Its use was also approved to treat chronic idiopathic constipation. (en)
  • Tegaserode é um fármaco agonista parcial dos receptores 5-HT4 da serotonina. Tem como principais funções agir contra os efeitos da constipação intestinal crônica e síndrome do cólon irritável. (pt)
  • Тегасерод — синтетичний лікарський засіб, що застосовується для лікування захворювань травної системи, який є стимулятором серотонінових рецепторів, та має прокінетичну дію, що застосовується перорально. (uk)
  • Tegaserod è un agonista dei recettori 5-HT4, utilizzato per il trattamento della sindrome dell'intestino irritabile e della costipazione. Il farmaco è prodotto e venduto dalla società farmaceutica Novartis con il nome commerciale di Zelnorm e Zelmac. Approvato dalla Food and Drug Administration (FDA) degli USA nel 2002, è stato successivamente ritirato dal mercato nel 2007, a causa delle preoccuppazioni della FDA circa i possibili effetti avversi cardiovascolari. Prima di allora tegaserod era l'unico farmaco approvato dalla FDA per contribuire ad alleviare il disagio addominale, il senso di gonfiore e la costipazione associata alla sindrome del colon irritabile. Il suo uso era stato approvato anche per il trattamento della costipazione idiopatica cronica. Attualmente, tegaserod può essere (it)
rdfs:label
  • تيجاسيرود (ar)
  • Tegaserod (de)
  • Tegaserod (es)
  • Tegaserod (it)
  • Tegaserode (pt)
  • Tegaserod (en)
  • Тегасерод (uk)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License